Fig. 3: RIPK1 knockout arrests cell cycle progression.
From: Necroptotic signaling orchestrates glioblastoma malignancy and potentiates temozolomide response
A The cell proliferation rate of U251 cells treated with RIPK1 inhibitor (Nec-1, 10 μM) or MLKL inhibitor (NSA, 10 μM) for 12 h, as determined by the CCK-8 assay. B Immunoblots of the indicated protein expression in WT U251 cells, RIPK1-KO U251 cells, and RIPK1-KO cells rescued with RIPK1-Flag. C Quantitative analysis of the relative protein levels in (B). D U251 cells were seeded on 6-well plates and the colony formation assays were visualized on day 14. Scale bar, 10 mm. E Cell proliferation rate of U251 cells with different genotypes, as measured by the CCK8 assay. F Immunoblot and densitometric quantification of cell cycle-related proteins in A172 cells 36 h post-transfection with negetive control (NC) or RIPK1-targeting siRNAs. Flow cytometry analysis of cell cycle distribution in A172 (G) and U251 (H) cells following RIPK1 depletion. Data are presented as mean ± SD. Statistical analysis was performed using the Student’s t test. *p < 0.05, **p < 0.01, ***p < 0.001; ns no significance.
